Open Drug Discovery Center for Alzheimer's Disease

阿尔茨海默病开放药物发现中心

• 批准号: 10017139
• 负责人: ALLAN I LEVEY
• 金额: $ 127.57万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10017139
• 关键词: Accountability; Adopted; Alzheimer' s Disease; Antibodies; Biological; Chemicals; Collaborations; Communication; Communities; Community Outreach; Complementary DNA; Data; Decision Making; Educational workshop; Ensure; Evaluation; Financial compensation; Funding; Infrastructure; Institution; Intellectual Property; Investigation; Knowledge; Lead; Leadership; Methods; Modeling; Office of Administrative Management; Privatization; Reagent; Research; Research Personnel; Resource Development; Resources; Rights; Scientist; Series; Services; Structure; Testing; Therapeutic; Validation; Work; data management; design; drug discovery; experience; industry partner; meetings; novel; open data; outreach services; pre-clinical; programs; tool

The Open Drug Discovery Center for AD (Open-AD) Administrative and Data Management Core (Admin and Data Core) serves three functions: (1) to provide overall administrative organization, oversight and management for all work performed within the Open-AD, (2) to manage communications with external AD investigators across the community including for target prioritization, and (3) to support the open distribution of all Open-AD generated reagents, tools, probes, data, and knowledge for use by independent investigators. The Admin and Data Core will establish and implement administrative and management structures to ensure that the Center is appropriately meeting milestones and deliverables, is soliciting input and openly sharing assets across the community, and is working across Cores for effective evaluation and management of target programs as they move through the Center pipeline. In addition, the Admin Core will manage Open-AD interactions with the external research community so as to solicit and evaluate a community-prioritized set of targets across a diverse portfolio of therapeutic hypotheses, to identify domain experts that can serve as advisors and partners to guide decisions around each therapeutic hypothesis that is selected, and to identify researchers that will use the assets developed by the Center to test these (and other) therapeutic hypotheses. Interactions with the external research community will be performed through the Open-AD AD expert panel, the External Advisory Board, an annual Open-AD meeting, target-specific workshops, and through the Agora platform (formerly called the AMP-AD Wall of Targets, agora.ampadportal.org). In order to invite the entire AD research community to participate in our investigation of novel targets, the proposed Open-AD Center will adopt a radically open approach to target validation and drug discovery. All Open-AD investigators have agreed to place all data, knowledge, reagents, and tools including chemical and biological probes into the open domain with no intellectual property claims. To support wide distribution and encourage reuse, Open-AD will donate the rights to distribute any reagent to commercial suppliers, non-exclusively and for no compensation. All Center activities will be performed in the open using the Open-AD collaboration workspace. All resources, data, and knowledge developed for each therapeutic approach will be disseminated using standard resource (AddGene for cDNA clones, Thermo Fisher for antibodies, etc) – and all information will be summarized and registered through the Agora platform.

AD 开放药物发现中心 (Open-AD) 管理和数据管理核心（Admin 和 数据核心）具有三个功能：（1）提供总体行政组织、监督和管理 对于 Open-AD 内执行的所有工作，(2) 管理与外部 AD 研究人员的通信 社区，包括目标优先级，以及 (3) 支持所有 Open-AD 生成的开放分发 供独立研究人员使用的试剂、工具、探针、数据和知识。管理和数据核心 将建立并实施行政和管理结构，以确保中心适当地 满足里程碑和可交付成果，正在征求意见并在整个社区公开共享资产，并且 跨核心工作，以便在目标计划进展过程中对其进行有效评估和管理 中心管道。此外，管理核心将管理 Open-AD 与外部研究的交互 社区，以便在不同的投资组合中征求和评估一组社区优先的目标 治疗假设，以确定可以作为顾问和合作伙伴来指导决策的领域专家 围绕所选的每个治疗假设，并确定将使用这些资产的研究人员 由该中心开发来测试这些（和其他）治疗假设。与外部研究的互动 社区将通过 Open-AD AD 专家小组、外部顾问委员会、年度 Open-AD 会议、针对特定目标的研讨会以及通过 Agora 平台（以前称为 AMP-AD Wall） 目标，agora.ampadportal.org）。为了邀请整个 AD 研究界参与我们的 对新目标的研究，拟议的 Open-AD 中心将采用一种彻底开放的方法来确定目标 验证和药物发现。所有 Open-AD 研究人员均同意将所有数据、知识、试剂、 以及工具，包括进入开放领域的化学和生物探针，没有知识产权声明。到 支持广泛分发并鼓励重复使用，Open-AD 将捐赠分发任何试剂的权利 商业供应商，非独家且无补偿。所有中心活动将在 使用 Open-AD 协作工作区打开。为每个项目开发的所有资源、数据和知识 将使用标准资源（用于 cDNA 克隆的 AddGene、Thermo Fisher 抗体等）——所有信息将通过 Agora 平台进行汇总和登记。